Consistently, Ki-67 IHC staining assay revealed that VIP treatment markedly reduced HCC proliferation in the HCC xenograft mouse model with greater inhibition in mice with HCCLM3-VIPR1 implant than in mice with HCCLM3-vector implant (Fig. 3C). This evidence concerns the gene VIPR1 and hepatocellular carcinoma.